Rosenkranz Moritz, Kerimi Nina, Takenova Madina, Impinen Antti, Mamyrov Mirlan, Degkwitz Peter, Zurhold Heike, Martens Marcus-Sebastian
Department of Psychiatry and Psychotherapy, Center for Interdisciplinary Addiction Research of Hamburg University (CIAR), University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Regional Office for Central Asia, United Nations Office on Drugs and Crime (UNODC), 26 Bukeykhan Street, UN House, 010000, Astana, Kazakhstan.
Harm Reduct J. 2016 Jan 27;13:3. doi: 10.1186/s12954-016-0093-2.
In Central Asia, there is a need to update information about the situation of people who use (opioid) drugs (PWUD), especially regarding their access to and utilization of health care services. The aim of the study was to gather information about two different groups of drug users in Kazakhstan and Kyrgyzstan.
In 2013, two groups of PWUD were recruited in Kazakhstan and in Kyrgyzstan in order to gather quantitative data via interviewer-administered questionnaires. PWUD registered with the Narcological Register were allocated to group A while non-registered PWUD were allocated to group B. Interviews were conducted in the office of the Narcological Register as well as in low-threshold facilities. Participants reported about their drug use patterns, health status, and utilization of health services as well as barriers to utilization.
The sample consisted of N = 600 PWUD (301 registered and 299 non-registered PWUD) from Kazakhstan and N = 900 PWUD (450 registered and 450 non-registered PWUD) from Kyrgyzstan. Both groups-registered (group A) and non-registered (group B)-consisted of mainly male long-term intravenous opioid users. We found high rates of current (last 30 days) opioid use (group A up to 70%; group B up to 84%). Most PWUD were burdened with poor physical and mental health. The prevalence of infectious diseases added up to 19% (group A) or 13% (group B) regarding HIV, 56% (group A) or 30% (group B) regarding HCV, and 24% (group A) or 20% (group B) regarding tuberculosis. Registered and non-registered PWUD reported high rates (95 or 82%) of lifetime use of health services for PWUD. Drug-related services were utilized less often, especially among the non-registered PWUD (13%). The most important barriers preventing PWUD from accessing services were the belief not to need treatment, doubts about the effectiveness of treatment, mistrust of treatment regime/staff, and fear of being registered with the Narcological Register (mainly group B).
Results show that access to the health care system for non-registered PWUD is realized mainly through low-threshold facilities. Opioid substitution treatment, which is an important pillar in the treatment of PWUD, is normally only available for those registered with the Narcological Register. Instead, access to opioid substitution treatment (especially in Kazakhstan) should be expanded and granted without prior registration, as this poses an important barrier for PWUD's utilization of drug treatment services. Further, there seems to be a need for the provision of specific and target group-related information about drug treatment services in order to reduce existing reservations among PWUD as to the necessity and effectiveness of modern drug treatment.
在中亚地区,有必要更新关于使用(阿片类)药物者(PWUD)状况的信息,特别是他们获得和利用医疗保健服务的情况。本研究的目的是收集哈萨克斯坦和吉尔吉斯斯坦两组不同吸毒者的信息。
2013年,在哈萨克斯坦和吉尔吉斯斯坦招募了两组PWUD,以便通过访谈员管理的问卷收集定量数据。在戒毒登记处登记的PWUD被分配到A组,未登记的PWUD被分配到B组。访谈在戒毒登记处办公室以及低门槛机构进行。参与者报告了他们的吸毒模式、健康状况、医疗服务利用情况以及利用障碍。
样本包括来自哈萨克斯坦的600名PWUD(301名登记和299名未登记的PWUD)以及来自吉尔吉斯斯坦的900名PWUD(450名登记和450名未登记的PWUD)。登记组(A组)和未登记组(B组)均主要由长期静脉注射阿片类药物的男性使用者组成。我们发现当前(过去30天)阿片类药物使用率很高(A组高达70%;B组高达84%)。大多数PWUD身心健康状况不佳。传染病患病率方面,艾滋病毒感染率A组为19%,B组为13%;丙型肝炎病毒感染率A组为56%,B组为30%;结核病感染率A组为24%,B组为20%。登记和未登记的PWUD报告称,一生中使用过针对PWUD的医疗服务的比例很高(分别为95%或82%)。与毒品相关的服务使用频率较低,尤其是在未登记的PWUD中(13%)。阻碍PWUD获得服务的最重要障碍是认为不需要治疗、对治疗效果存疑、不信任治疗方案/工作人员以及害怕在戒毒登记处登记(主要是B组)。
结果表明,未登记的PWUD主要通过低门槛机构获得医疗保健系统服务。阿片类药物替代治疗是PWUD治疗的重要支柱,通常仅提供给在戒毒登记处登记的人员。相反,应扩大阿片类药物替代治疗的可及性(特别是在哈萨克斯坦),且无需事先登记即可提供,因为这是PWUD利用药物治疗服务的一个重要障碍。此外,似乎有必要提供关于药物治疗服务的特定且与目标群体相关的信息,以减少PWUD对现代药物治疗必要性和有效性的现有疑虑。